How Psychedelic Biotech Is Reshaping Mental Health | Eric So - CEO, Helus Pharma

Episode notes

Send us Fan Mail Psychedelic medicine is no longer fringe science - it’s now part of White House policy discussions, FDA fast-track programs, and a rapidly emerging neuropsychiatric industry. But can these therapies truly become scalable standards of care? Eric So is Co-Founder and Executive Chairman of Helus Pharma ( ), a company focused on developing next-generation serotonergic therapies for mental illness and advancing the broader field of psychedelic-assisted psychiatry. With a multidisciplinary background spanning science, law, finance, and entrepreneurship, Eric has spent his career building and scaling public and private companies across emerging sectors. Before launching Helus Pharma in 2019, Eric was involved with a number of high-growth ventures, including leadership roles at Globalive Technology and Therapix Biosciences Ltd., where he gained firsthand experience navigating the intersection of biotechnology innovation, regulation, and capital markets. He earned a Bachelor of Science in Cell Biology and Anatomy from McGill University before obtaining his law degree from University of Windsor.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• Your mental fitness bootcamp with Maya Raichoora [REPLAY]Strategy & Tragedy: CEO Stories with Steph Melodia · on neuroscience80 / 100
• 101: Rapid Transformation - AI, Psychedelics & Leadership with Dr Catriona WallaceHabits of Leadership · on Psychedelics73 / 100
• Ep 216, Failure Is A Component Of SuccessConflict Managed · on neuroscience69 / 100
• Dr. Kristen Gilliland: A Mother's Journey from Neuroscience to AdvocacyHeart of the Matter · on neuroscience64 / 100
• 077 Gabe Derita: Neuroscience & IkigaiUnbound with Chris DuBois · on neuroscience64 / 100
• Ep 201: The Leadership School Hidden Inside the Black ChurchThe Culture Soup Podcast®️ · on neuroscience63 / 100

• Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100
• Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-Colton
• Reversing Cellular Age: The Scientist Who Helped Create iPS Cells Reveals What’s Next - Dr. Koji Tanabe, Ph.D. - Founder and CEO, I Peace Inc.
• The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart Institute
• The Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen